Stimulus Responsive Nanocarrier for Enhanced Antitumor Responses Against Hepatocellular Carcinoma
Introduction Hepatocellular carcinoma (HCC) remains a predominant form of liver cancer with relative 18% five-year survival rate.1,2 The insidious HCC often results in patients being diagnosed at intermediate or advanced stages.3 Despite notable progress …